Supernus Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8684591089
USD
45.10
0.98 (2.22%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Dec'18
Net Sales
661.82
607.52
667.24
579.77
520.40
392.75
408.90
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
661.82
607.52
667.24
579.77
520.40
392.75
408.90
Raw Material Cost
158.32
168.64
172.85
107.65
72.46
16.66
15.36
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
2.42
7.07
23.42
23.75
22.71
18.11
Selling and Distribution Expenses
335.78
336.36
377.22
298.06
192.28
158.43
159.89
Other Expenses
10.64
8.67
6.45
4.94
4.79
4.64
7.11
Total Expenditure (Excl Depreciation)
600.46
594.12
621.62
478.58
336.40
244.18
264.45
Operating Profit (PBDIT) excl Other Income
61.4
13.4
45.599999999999994
101.19999999999999
184
148.6
144.4
Other Income
16.20
10.45
21.69
10.57
18.70
21.62
13.84
Operating Profit (PBDIT)
157.97
108.72
152.93
144.36
222.70
180.42
165.35
Interest
0.00
2.42
7.07
23.42
23.75
22.71
18.11
Exceptional Items
20.31
-18.67
0.51
-15.17
-10.30
0.00
0.00
Gross Profit (PBDT)
503.50
438.88
494.39
472.12
447.94
376.10
393.54
Depreciation
80.41
84.86
85.63
32.59
20.00
10.22
7.06
Profit Before Tax
97.87
2.77
60.74
73.17
168.65
147.49
140.18
Tax
24.00
1.45
0.03
19.75
41.70
34.43
29.18
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
73.86
1.32
60.71
53.42
126.95
113.06
110.99
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
73.86
1.32
60.71
53.42
126.95
113.06
110.99
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
73.86
1.32
60.71
53.42
126.95
113.06
110.99
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
1,035.73
921.52
886.20
815.85
744.86
595.43
453.02
Earnings per share (EPS)
1.32
0.02
1.04
0.98
2.36
2.1
2.05
Diluted Earnings per share
1.32
0.02
1.04
0.98
2.36
2.1
2.05
Operating Profit Margin (Excl OI)
9.27%
2.21%
6.84%
17.45%
35.36%
37.83%
35.33%
Gross Profit Margin
26.94%
14.42%
21.94%
18.24%
36.25%
40.16%
36.01%
PAT Margin
11.16%
0.22%
9.1%
9.21%
24.39%
28.79%
27.14%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Dec 2024 is 8.94% vs -8.95% in Dec 2023

stock-summary

Consolidate Net Profit

YoY Growth in year ended Dec 2024 is 5,584.62% vs -97.86% in Dec 2023

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2024 is 44.25% vs -25.08% in Dec 2023

stock-summary

Interest

YoY Growth in year ended Dec 2024 is -100.00% vs -66.20% in Dec 2023

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2024 has improved from Dec 2023

Compare Annual Results Of Supernus Pharmaceuticals, Inc. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(USD)
Change(%)
Net Sales
661.82
1.04
660.78
63,536.54%
Other Operating Income
0.00
0.00
0.00
Total Operating income
661.82
1.04
660.78
63,536.54%
Raw Material Cost
158.32
2.79
155.53
5,574.55%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0.00
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
335.78
99.74
236.04
236.66%
Other Expenses
10.64
23.74
-13.10
-55.18%
Total Expenditure (Excl Depreciation)
600.46
339.89
260.57
76.66%
Operating Profit (PBDIT) excl Other Income
61.36
-338.85
400.21
118.11%
Other Income
16.20
40.45
-24.25
-59.95%
Operating Profit (PBDIT)
157.97
-295.62
453.59
153.44%
Interest
0.00
0.00
0.00
Exceptional Items
20.31
0.00
20.31
Gross Profit (PBDT)
503.50
-1.75
505.25
28,871.43%
Depreciation
80.41
2.79
77.62
2,782.08%
Profit Before Tax
97.87
-298.41
396.28
132.80%
Tax
24.00
0.00
24.00
Provisions and contingencies
0
0
0.00
Profit After Tax
73.86
-298.41
372.27
124.75%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
73.86
-298.41
372.27
124.75%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
73.86
-298.41
372.27
124.75%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
1,035.73
1,324.81
-289.08
-21.82%
Earnings per share (EPS)
1.32
-3.69
5.01
135.77%
Diluted Earnings per share
1.32
-3.69
5.01
135.77%
Operating Profit Margin (Excl OI)
9.27%
-32,613.47%
0.00
32,622.74%
Gross Profit Margin
26.94%
-28,452.65%
0.00
28,479.59%
PAT Margin
11.16%
-28,720.69%
0.00
28,731.85%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 66.18 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 8.94% vs -8.95% in Dec 2023

Annual - Consolidate Net Profit
Consolidate Net Profit 7.39 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 5,584.62% vs -97.86% in Dec 2023

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 14.18 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 44.25% vs -25.08% in Dec 2023

Annual - Interest
Markets Mojo
No Interest in the last few periods
Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 9.27%
in Dec 2024

Figures in %
stock-summary

YoY Growth in year ended Dec 2024 has improved from Dec 2023